Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients
- 31 December 1978
- journal article
- Published by Elsevier BV in Progress in Cardiovascular Diseases
- Vol. 21 (3), 195-206
- https://doi.org/10.1016/0033-0620(78)90025-7
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977
- A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MANThe Lancet, 1977
- Possible Role of Renin in Hypertension as Suggested by Renin-Sodium Profiling and Inhibition of Converting EnzymeNew England Journal of Medicine, 1977
- Proposed Mechanisms of Propranolol's Antihypertensive Effect in Essential HypertensionNew England Journal of Medicine, 1976
- Unexpected pressor responses to propranolol in essential hypertension: An interaction between renin, aldosterone and sympathetic activityAmerican Journal Of Medicine, 1976
- Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker)American Journal Of Medicine, 1976
- Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patientsAmerican Journal Of Medicine, 1976
- Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man.JCI Insight, 1976
- Use of an Angiotensin II Antagonist (Saralasin) in the Recognition of “Angiotensinogenic” HypertensionNew England Journal of Medicine, 1975
- Propranolol Inhibition of Renin SecretionNew England Journal of Medicine, 1972